Abstract

<div>Abstract<p><b>Purpose:</b> The effectiveness of NK cell infusions to induce leukemic remission is limited by lack of both antigen specificity and <i>in vivo</i> expansion. To address the first issue, we previously generated a bispecific killer engager (BiKE) containing single-chain scFv against CD16 and CD33 to create an immunologic synapse between NK cells and CD33<sup>+</sup> myeloid targets. We have now incorporated a novel modified human IL15 crosslinker, producing a 161533 trispecific killer engager (TriKE) to induce expansion, priming, and survival, which we hypothesize will enhance clinical efficacy.</p><p><b>Experimental Design:</b> Reagents were tested in proliferation and functional assays and in an <i>in vivo</i> xenograft model of AML.</p><p><b>Results:</b> When compared with the 1633 BiKE, the 161533 TriKE induced superior NK cell cytotoxicity, degranulation, and cytokine production against CD33<sup>+</sup> HL-60 targets and increased NK survival and proliferation. Specificity was shown by the ability of a 1615EpCAM TriKE to kill CD33-EpCAM<sup>+</sup> targets. Using NK cells from patients after allogeneic stem cell transplantation when NK cell function is defective, the 161533 TriKE restored potent NK function against primary AML targets and induced specific NK cell proliferation. These results were confirmed in an immunodeficient mouse HL-60-Luc tumor model where the 161533 TriKE exhibited superior antitumor activity and induced <i>in vivo</i> persistence and survival of human NK cells for at least 3 weeks.</p><p><b>Conclusions:</b> Off-the-shelf 161533 TriKE imparts antigen specificity and promotes <i>in vivo</i> persistence, activation, and survival of NK cells. These qualities are ideal for NK cell therapy of myeloid malignancies or targeting antigens of solid tumors. <i>Clin Cancer Res; 22(14); 3440–50. ©2016 AACR</i>.</p><p><i>See related commentary by Talmadge, p. 3419</i></p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.